Edwards Lifesciences Corp (EW)vsHaemonetics Corporation (HAE)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
HAE
Haemonetics Corporation
$55.93
-1.29%
HEALTHCARE · Cap: $2.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 360% more annual revenue ($6.07B vs $1.32B). EW leads profitability with a 17.7% profit margin vs 13.3%. HAE appears more attractively valued with a PEG of 0.90. HAE earns a higher WallStSmart Score of 67/100 (B-).
EW
Buy55
out of 100
Grade: C
HAE
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Margin of Safety
+66.2%
Fair Value
$169.88
Current Price
$55.93
$113.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.0%
Earnings expanding 28.4% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Distress zone — elevated risk
Elevated debt levels
Revenue declined 2.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : HAE
The strongest argument for HAE centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.90 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : HAE
The primary concerns for HAE are Altman Z-Score, Debt/Equity, Revenue Growth.
Key Dynamics to Monitor
EW profiles as a mature stock while HAE is a declining play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
HAE scores higher overall (67/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?